Kamphorst et al. (25) showed that 70% of lung cancer patients with disease progression had a delayed PD-1+CD8+ T cell response, whereas 80% of patients with clinical benefit expressed PD-1+CD8+ T cell. This evidence concerns the gene CD8A and lung carcinoma.